Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism.
Phosphorothioate oligonucleotides (PS ODNs) prolong the activated partial thromboplastin time in human plasma by inhibition of intrinsic tenase (factor IXa-factor VIIIa) activity. This inhibition was characterized using ISIS 2302, a 20-mer antisense PS ODN. ISIS 2302 demonstrated hyperbolic, mixed-type inhibition of factor X activation by the intrinsic tenase complex. The decrease in V(max(app)) was analyzed by examining complex assembly, cofactor stability, and protease catalysis. ISIS 2302 did not inhibit factor X activation by the factor IXa-phospholipid complex, or significantly affect factor VIII-phospholipid affinity. Inhibitory concentrations of ISIS 2302 modestly decreased the affinity of factor IXa-factor VIIIa binding in the presence of phospholipid (K(D) = 11.5 vs 4.8 nM). This effect was insufficient to explain the reduction in V(max(app)). ISIS 2302 did not affect the in vitro half-life of factor VIIIa, suggesting it did not destabilize cofactor activity. In the presence of 30% ethylene glycol, the level of factor X activation by the factor IXa-phospholipid complex increased 3-fold, and the level of chromogenic substrate cleavage by factor IXa increased more than 50-fold. ISIS 2302 demonstrated partial inhibition of factor X activation by the factor IXa-phospholipid complex, and chromogenic substrate cleavage by factor IXa, only in the presence of ethylene glycol. Like the intact enzyme complex, ISIS 2302 demonstrated hyperbolic, mixed-type inhibition of chromogenic substrate cleavage by factor IXa (K(I) = 88 nM). Equilibrium binding studies with fluorescein-labeled ISIS 2302 demonstrated a similar affinity (K(D) = 92 nM) for the PS ODN-factor IX interaction. These results suggest that PS ODNs bind to an exosite on factor IXa, modulating catalytic activity of the intrinsic tenase complex.
Sheehan
J P
JP
Department of Medicine/Hematology, South Texas Veteran's Health Care System (Audie Murphy Division), University of Texas Health Science Center at San Antonio, 78284, USA. sheehan@uthscsa.edu
Phan
T M
TM
D000494:Allosteric Regulation; D001665:Binding Sites / Q000187:drug effects; D001667:Binding, Competitive; D002384:Catalysis; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D019855:Ethylene Glycol / Q000494:pharmacology; D015949:Factor IXa / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015944:Factor VIIIa / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D046911:Macromolecular Substances; D009363:Neoplasm Proteins; D020319:Oligodeoxyribonucleotides, Antisense / Q000378:metabolism / Q000494:pharmacology; D010743:Phospholipids / Q000037:antagonists & inhibitors / Q000378:metabolism; D054735:Phosphorothioate Oligonucleotides; D015842:Serine Proteinase Inhibitors / Q000145:classification / Q000494:pharmacology*; D013873:Thionucleotides / Q000378:metabolism / Q000494:pharmacology*
D046911:Macromolecular Substances; D009363:Neoplasm Proteins; D020319:Oligodeoxyribonucleotides, Antisense; D010743:Phospholipids; D054735:Phosphorothioate Oligonucleotides; D015842:Serine Proteinase Inhibitors; D013873:Thionucleotides; D015944:Factor VIIIa; D015949:Factor IXa; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant; D019855:Ethylene Glycol; C089753:alicaforsen